Paper Details
- Home
- Paper Details
Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network.
Author: ChaginKaren, DjousseLuc, FraemanKathy H, GagnonDavid R, HallSusan A, NelsonJeanenne J, NordstromBeth L, ShantakumarSumitra, van Herk-SukelMyrthe P P
Original Abstract of the Article :
Pazopanib received US Food and Drug Administration approval in 2009 for advanced renal cell carcinoma. During clinical development, liver chemistry abnormalities and adverse hepatic events were observed, leading to a boxed warning for hepatotoxicity and detailed label prescriber guidelines for liver...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407814/
データ提供：米国国立医学図書館（NLM）
Pazopanib: Assessing Prescriber Compliance with Liver Monitoring Guidelines
This study focuses on the important issue of [drug safety] and investigates prescriber compliance with liver monitoring guidelines for pazopanib, a medication used to treat advanced renal cell carcinoma. The study aimed to assess the extent to which prescriber practices aligned with the detailed guidelines outlined in the drug's label, which include a boxed warning for hepatotoxicity. The researchers conducted a [cohort study] using data from a distributed research network to analyze prescriber practices in the post-approval setting. The study concluded that prescriber compliance with liver monitoring guidelines for pazopanib varied significantly, highlighting the need for enhanced education and awareness among prescribers regarding the importance of vigilant liver monitoring in patients receiving this medication. The study emphasizes the crucial role of healthcare professionals in ensuring patient safety by adhering to established guidelines.
Pazopanib: Assessing Prescriber Compliance with Liver Monitoring Guidelines
This study highlights the importance of prescriber compliance with liver monitoring guidelines for pazopanib. The study found that compliance varied significantly, underscoring the need for enhanced education and awareness among prescribers regarding the importance of vigilant liver monitoring in patients receiving this medication.
Pazopanib: Assessing Prescriber Compliance with Liver Monitoring Guidelines
Imagine pazopanib as a powerful desert plant, capable of battling cancer but also carrying the risk of liver toxicity. Liver monitoring guidelines act like a skilled desert guide, providing essential instructions for safely navigating the terrain. This study suggests that we need to improve the awareness of these guidelines among desert explorers (prescribers) to ensure the safe use of this powerful medicine.
Dr.Camel's Conclusion
This study emphasizes the importance of prescriber compliance with liver monitoring guidelines for pazopanib. The study found that compliance varied significantly, underscoring the need for enhanced education and awareness among prescribers regarding the importance of vigilant liver monitoring in patients receiving this medication.
Date :
- Date Completed 2020-04-28
- Date Revised 2021-12-04
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.